Table 8.
Comparison of the results of this review with Balk 2016 and Aung 2018a
| Balk 2016 | Aung 2018 | This review | ||||
| Number of people experiencing events | RR (95% CI) | Number of people experiencing events | RR (95% CI) | No of people experiencing events | RR (95% CI) | |
| All‐cause mortality | 8480 | 0.97 (0.92 to 1.03) | — | Not assessed | 8647 | 0.98 (0.93 to 1.03) |
| Cardiovascular deaths | 3799 | 0.92 (0.82 to 1.02) | — | Not assessed | 4763 | 0.95 (0.87 to 1.03) |
| CVD events (MACCEs in Balk 2016) | 8085 | 0.96 (0.91 to 1.02) | 12001 | 0.97 (0.93 to 1.01) | 15614 | 0.99 (0.94 to 1.04) |
| CHD deaths | — | Not pooled | 2695 | 0.93, (0.83 to 1.03) | 1791 | 0.93 (0.79 to 1.09) |
| CHD events | — | Not assessed | 6273 | 0.96, (0.90 to 1.01) | 5865 | 0.93 (0.88 to 0.97) |
| Stroke | 1467 | 0.98 (0.88 to 1.09) | 1713 | 1.03 (0.93 to 1.13) | 1871 | 1.06 (0.96, 1.16) |
| Arrhythmia | — | Not pooled | — | Not assessed | 3788 | 0.97 (0.90 to 1.05) |
CHD: coronary heart disease; CI: confidence interval; CVD: cardiovascular disease; MACCE: major adverse cerebrovascular or cardiovascular event; RR: risk ratio.
aMeta‐analysis of effects of LCn3 in Balk 2016 and Aung 2018 systematic reviews, comparing their findings with our findings for our primary outcomes.